Verdejo J, Iniguez A, Polo R, Martinez ML, Inchaustegui L, Enriquez A, Gonzalez-Lahoz JM; International Conference on AIDS.
Int Conf AIDS. 1994 Aug 7-12; 10: 188 (abstract no. PB0182).
Instituto de Salud Carlos III, Madrid, Spain.
We evaluate hepatobiliary complications and serological markers in viral hepatitis in a prospective study since February 1992. RESULTS: Patients 108 (51 AIDS-CDC 1993). Average follow-up 245 days (range 60-690). Sex: M 81/F 27. Average age 31.8 (range 21-69). Risk group: IVDU 72, Homosexual 27, Heterosexual 8, Transfusion 1. We obtained the following results: (I) Hepatobiliary complications 92 in 78 patients (78/108: 70.3%). Complications: chronic viral hepatitis 25 (19 HCV, 3 HBV, 1 HCV+HBV, 1 HBV+HDV, 1 HBV+HCV+HDV); without filiation 17; mild alterations 14 (GPT and/or GGT < 1.5 times limit of normal); infectious diseases 10 (cholangitis/chole-cystitis 6, tuberculosis 3, bacteremia 1); hepatotoxic agents 10; multiple factors 8 (HCV+Alcohol 7, HCV+hepatotoxic agents 1); alcoholism 1; acute viral hepatitis (HCV) 2; other 5 (2 angioma, 1 hepatocarcinoma, 1 cholelitiasis, 1 hydatid cyst). (II) Serological markers: 1) HBV: a) HBsAg+ 8% (HBeAg+ 50%) (Co-infection HDV 28.5%), b) HBsAg- with anti-HBc+ 72.7%, c) HCV 62.7% (we exclude the patients with EIA+ and a second-generation RIBA test indeterminate or negative). CONCLUSIONS: 1) Hepatobiliary complications are common in HIV-patients (71.5%). 2) chronic viral hepatitis HCV is the most frequent disease due to the 66.6% are IVDU. 3) In our experience, serological markers of HBV and HCV are detected in 81.1% (8% with HBsAg+) and 62.7% respectively.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Alanine Transaminase
- Carcinoma, Hepatocellular
- HIV Infections
- HIV Seropositivity
- Hepacivirus
- Hepatitis, Viral, Human
- Humans
- Prospective Studies
Other ID:
UI: 102208452
From Meeting Abstracts